Company: BIAF
Filing Date: 2025-06-02
Form Type: DEF 14A
Source: 0001641172-25-013280
Chunk: 15

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-06-02
Form: DEF 14A
Chunk 15
---
 our directors, officers, and employees who have access to material nonpublic
information (“MNPI”) about the Company and from giving MNPI to others who may trade on the basis of such information.
Under the policy, Timothy Zannes, the Company’s Executive Vice President, Secretary, and General Counsel, is designated as the
Company’s Insider Trading Compliance Officer (the “Compliance Officer”). Prior to engaging in transfers
of Company securities intended to comply with the affirmative defense provided under Rule 10b5-1 promulgated under the Exchange Act,
employees, officers, and directors must receive the Compliance Officer’s approval. The Trading Policy is annexed as an exhibit
to our Annual Report on Form 10-K for the year ended December 31, 2024.

Prohibition against Short Sales and Hedging

Pursuant to our Insider Trading Policy,
we prohibit our employees, officers, and directors from trading in any interest or position relating to the future price of Company
securities, such as a put, call, or short sale (including a short sale “against the box”).

Role of the Board in Risk Oversight

One of the key functions of the Board is informed
oversight of the Company’s risk management process. The Board does not have a standing risk management committee but rather administers
its oversight function directly through the Board as a whole and through its standing committees that address risks inherent in their
respective oversight areas. In particular, the Board is responsible for monitoring and assessing strategic risk exposure. The Audit Committee
has the responsibility to consider and discuss (i) the Company’s major financial risk exposures and the steps management has taken
to monitor and control these exposures, which includes establishing guidelines and policies to govern the process by which risk assessment
and management is undertaken and (ii) policies regarding information technology security and protection from cyber risks The Audit Committee
also monitors compliance with legal and regulatory requirements, in addition to oversight of the performance of the Company’s external
audit function.

The Nominating and Corporate Governance Committee
monitors the effectiveness of the Company’s corporate governance guidelines. The Compensation Committee assesses and monitors whether
any of the Company’s compensation policies and programs has the potential to encourage excessive risk-taking. While each committee
is responsible for evaluating certain risks and overseeing the management of such risks, the full Board is regularly informed of such
risks through committee reports and otherwise. While the Board oversees the Company’s overall risk management, the day-to-day management
processes are executed by the